CervoMed Stock (NASDAQ:DFFN)
Previous Close
$3.99
52W Range
$4.14 - $14.37
50D Avg
$5.06
200D Avg
$7.07
Market Cap
$8.98M
Avg Vol (3M)
$47.81K
Beta
1.76
Div Yield
-
DFFN Company Profile
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
DFFN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NXTC | NextCure, Inc. |
| AKTX | Akari Therapeutics, Plc |
| JAGX | Jaguar Health, Inc. |
| CAPR | Capricor Therapeutics, Inc. |
| ACST | Acasti Pharma Inc. |
| PULM | Pulmatrix, Inc. |
| TNXP | Tonix Pharmaceuticals Holding Corp. |
| CBIO | Crescent Biopharma, Inc. |
| TENX | Tenax Therapeutics, Inc. |
| CLRB | Cellectar Biosciences, Inc. |
| BPTH | Bio-Path Holdings, Inc. |
| SLNO | Soleno Therapeutics, Inc. |
| MNPR | Monopar Therapeutics Inc. |